In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Lee Ph.D., President at the CDMO Division of Lubrizol Life Science Health (LLS). Rob has over 30 years’ experience in the pharmaceutical R&D space and his areas of expertise include drug delivery, formulation development, analytical sciences and sterile manufacturing. With a Ph.D. in Physical Bioorganic Chemistry, Rob has published more than three dozen articles and five book chapters. Plus, he holds 11 issued patents and 15 provisional or PCT patent applications. He has worked for some major companies in the sector and was appointed President of the CDMO Division of LLS after 10 years with the business.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob Lee, covering the new paradigm for drug development and manufacturing after the speed to market achieved by the COVID-19 vaccines. Rob then explains how patient-friendly dosage forms will continue to play an increasingly important role in the future. Rob also gives us an idea of the types of molecules and projects coming through the pipeline at the moment and what is in store for LLS. Lastly Rob shares what it’s been like to transition from a scientist to a leader while keeping science at the heart of everything he does. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.